Akero Therapeutics, Inc. AKRO

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
—
Insufficient data

Ranked against 712 peers in Biotechnology

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where AKRO ranks in Biotechnology

Akero Therapeutics, Inc. ranks #654 of 713 scored companies in Biotechnology by moat score — the top 92%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
650 Alzamend Neuro, Inc. ALZN 6/100 Weak
651 Bio-Path Holdings, Inc. BPTH 4/100 Weak
652 Aadi Bioscience, Inc. AADI 0/100 Weak
653 Adaptimmune Therapeutics plc ADAP 0/100 Weak
654 Akero Therapeutics, Inc. AKRO 0/100 Weak
655 Allakos Inc. ALLK 0/100 Weak
656 AlloVir, Inc. ALVR 0/100 Weak
657 180 Life Sciences Corp. ATNF 0/100 Weak
658 180 Life Sciences Corp. ATNFW 0/100 Weak

See every Biotech / Pre-Revenue company ranked by moat score →

How AKRO scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Not measurable · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Not measurable · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding AKRO's moat

What is Akero Therapeutics, Inc.'s moat score?

Akero Therapeutics, Inc. (AKRO) scores 0 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #654 of 713 scored companies in Biotechnology, the top 92%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology.

How does Akero Therapeutics, Inc. compare with other Biotechnology companies?

Akero Therapeutics, Inc. ranks #654 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Adaptimmune Therapeutics plc (ADAP) at 0 just above it and Allakos Inc. (ALLK) at 0 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Akero Therapeutics, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Akero Therapeutics, Inc.?

The Corporate Default template measures 6 defenses, and AKRO scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (not measurable), Resilience (not measurable), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000